Prostaglandin release from preparations used vaginally for the induction of labour.
The release and absorption profiles from the vagina of PGE2 in different vehicles used for cervical ripening and labour induction have been studied observing changes in concentrations of PGE metabolite (PGEM) and PGF metabolite (PGFM). In all groups a rise in PGEM concentration occurred over the 6 hour observation time but with wide variation. The profiles obtained differed markedly between the preparations under investigation correlating with the uterine contractions generated. PGFM generally showed little change. The model used could be explored further to enable modification of the vehicles used for PGE2 incorporation to achieve improved clinical results.
D000032:Abortion, Therapeutic; D000282:Administration, Intravaginal; D001682:Biological Availability; D015232:Dinoprostone; D004304:Dosage Forms; D005260:Female; D006801:Humans; D007751:Labor, Induced; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D014590:Uterine Contraction / Q000187:drug effects*
D004304:Dosage Forms; D011458:Prostaglandins E; D015232:Dinoprostone